What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Zilganersen showed a statistically significant preservation of gait speed over 61 weeks compared to control, with a mean difference of 33.3 percentage points (95% CI 1.44 to 65.25; p=0.041). However, the study was small (30 participants in the primary analysis) and the confidence interval was wide, indicating substantial uncertainty over the magnitude of the effect.
Does the economic case hold at the expected price? — Cost effectiveness
No economic model, ICER, or cost-utility analysis was identified. At a price of $285,000 per quarterly dose (the reported list price), costs are high, but without QALY data or an ICER, cost-effectiveness cannot be assessed.
Is there quality-of-life evidence payers weigh? — Quality of life
The trial included patient-centered instruments like Most Bothersome Symptom, PGIS, and PGIC, but no preference-based HRQoL instruments were reported. The lack of validated HRQoL scales and comprehensive data limits the assessment of HRQoL benefits.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Common adverse events were well characterized, with most being mild or moderate. Serious TEAEs were less frequent in the treatment group compared to control, but the small sample size and lack of detailed safety data limit the assessment of long-term safety. [Expert decision MG: grade set to A — Safety seems to be ok]
Was the drug compared against what payers expect? — Comparator Selection
The use of placebo/control plus supportive care was appropriate given the lack of an authorized disease-modifying treatment at the time. However, the comparator does not resolve how zilganersen changes the intensity or costs of supportive care.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population was predominantly White and included a narrow age range. The approved indication is broader than the trial population, particularly for infants and older adults, leading to concerns about representativeness.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Zilganersen requires specialist intrathecal administration, which exceeds the infrastructure needed for oral or home-administered therapy. This introduces significant system impact and potential barriers to integration.
Are the wider system costs understood? — Resource Use and Cost Implications
No budget-impact or resource-use information was presented. The high list price suggests significant cost implications, but without detailed data, the impact cannot be assessed.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The study was a randomized, double-blind, controlled trial, but it was small and combined phase 1–3 design. The lack of a full peer-reviewed publication and incomplete public protocol reporting limit the robustness of the evidence.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
The small sample size, wide confidence intervals, and lack of long-term data contribute to high uncertainty. The absence of sensitivity analyses and broader system impact assessments further limits confidence in the evidence.
